Comparative Analysis of the Anesthesia Effect of Cisatracurium Besylate and Mivacurium Chloride Otolaryngology Surgery

Shibin Huang¹ and Qi Li²

¹Department of Otolaryngology, The Second Affiliated Hospital of Jiaxing University, No. 1518, Huancheng North Road, Jiaxing, Zhejiang 314000, China
²Department of Anesthesiology, The Second Affiliated Hospital of Jiaxing University, No. 1518, Huancheng North Road, Jiaxing, Zhejiang 314000, China

Correspondence should be addressed to Qi Li; liqi_180602@sina.com

Received 7 May 2022; Revised 27 May 2022; Accepted 3 June 2022; Published 18 July 2022

Copyright © 2022 Shibin Huang and Qi Li. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The aim is to investigate and compare the anesthesia effect of cisatracurium besylate and mivacurium chloride otolaryngology surgery. Materials and Methods. 108 patients who underwent ENT surgery under general anesthesia in our hospital from November 2021 to March 2022 were recruited for retrospective analysis, in which patients in the experimental group A were anesthetized with cisatracurium besylate and patients in the experimental group B were anesthetized with mivacurium, and the anesthetic effects and recovery of the two groups were compared and analyzed. Results. There was no significant difference in mean arterial pressure, heart rate, and pulse oximetry levels between the two groups at the six time points of admission, anesthesia induction, intubation, end of operation, recovery of consciousness, and extubation (all \( P > 0.05 \)). The train of four stimulation values at end of operation, recovery of consciousness, extubation time, and eye-opening time of the experimental group B were significantly higher than those of the experimental group A (all \( P > 0.05 \)). The recovery time of self-consciousness, extubation time, and eye-opening time of the experimental group B were significantly shorter than those of the experimental group A, and the occurrence of agitation was significantly less than that of the experimental group A (all \( P > 0.05 \)). The total incidence of adverse conditions in the experimental group B was significantly lower than that in the experimental group A (\( P > 0.05 \)). Conclusion. Compared with cisatracurium besylate in otolaryngology surgery, mivacurium chloride anesthesia offers a promising route with respect to less impact on hemodynamics, faster postoperative recovery, absence of the accumulation of neuromuscular blockade, less adverse reactions, and higher safety.

1. Introduction

Ear, nose, and throat surgery is one of the most common clinical procedures [1] and includes a variety of types, such as ear surgery, including otitis media surgery, hearing reconstruction surgery, and surgical treatment of vertigo; rhinologic surgery, including correction of nasal structures, turbinate hypertrophy surgery, sinusitis surgery, and nasal tumor surgery; and laryngeal surgery, including tonsil surgery, adenoid surgery, and hypopharyngeal tumor surgery. ENT surgery is characterized by relatively short duration and intense stimulation of the nerves and muscles of the patient’s throat [2, 3]. Therefore, muscle relaxation and depth of anesthesia are highly demanded in otolaryngology surgery to ensure a quick anesthesia emergence after surgery. General anesthesia can be administered by tracheal intubation if the operation is difficult and if the intraoperative operation does not affect airway patency [4]; local anesthesia can be administered if the surgical site is superficial and the intraoperative operation does not affect airway patency. Local anesthesia is safer than general anesthesia or intravenous anesthesia [5].

There is convincing observational evidence supporting that among the anesthetic drugs, cisatracurium besylate has a significant muscle relaxant effect, and mivacurium chloride has fewer side effects. Cisatracurium besylate for injection, a white loose lump or powder with molecular formula of \( C_{65}H_{82}N_{2}O_{18}S_{2} \), is a moderate-acting, nondepolarizing skeletal...
muscle relaxant with an isoquinolinium benzyl ester structure and a neuromuscular blocker [6, 7]. Human clinical studies have shown that cisatracurium besylate binds to cholinergic receptors on the motor endplate to antagonize the action of acetylcholine, resulting in a competitive neuromuscular blockade [8, 9]. At present, it is predominantly used for surgery and other operations in intensive care treatment. Due to the characteristics of relaxing skeletal muscles and convenience to perform tracheal intubation and mechanical ventilation, it is thus used clinically as an adjuvant drug for general anesthesia or as a sedative in intensive care [10, 11]. Mivacurium chloride [12], a gray-white solid with a molecular formula of C58H80Cl2N2O14, is a short-acting benzylisoquinoline non-depolarizing muscle relaxant [13]. Clinically, it is majorly used in short-term surgical procedures and can be used as an adjuvant drug for general anesthesia during tracheal intubation and mechanical ventilation [14]. For example, mivacurium chloride is commonly used as the first-choice anesthetic in cystoscopic resection of bladder cancer [15]. Available findings indicate that it is the most effective and selective non-depolarizing inotropic drug available clinically, with the advantages of rapid onset of action, rapid recovery, few side effects, no drug accumulation, no adverse effects on the autonomic nervous system and cardiovascular system, and elimination half-life [16, 17]. However, there are few studies of clinical application of mivacurium chloride minor surgery, such as otolaryngology surgery, and there are also few related studies comparing the anesthetic effects of cisatracurium besylate and mivacurium chloride. To address the gap, this study was to investigate and compare the anesthesia effects of cisatracurium besylate and mivacurium chloride otolaryngology surgery, aiming to provide new ideas and routes for anesthesia.

2. Materials and Methods

2.1. General Information. A total of 108 patients who underwent otolaryngology surgery under general anesthesia in our hospital from November 2021 to March 2022 were retrospectively analyzed and were evenly allocated into an experimental group A and an experimental group B. This study has been reviewed and approved by the Medical Ethics Committee of the Second Affiliated Hospital of Jiaxing University, approval no. 9799/31.

2.2. Inclusion and Exclusion Criteria

2.2.1. Inclusion Criteria. Inclusion criteria are as follows: all patients combined with abnormal heart, liver, and kidney functions; patients combined with blood diseases or coagulation disorders; and research related drug allergies.

2.2.2. Exclusion Criteria. Exclusion criteria are as follows: patients combined with abnormal heart, liver, and kidney function disorders; and research related drug allergies.

3. Methods

Both groups of patients underwent routine anesthesia induction after entering the operating room. 1-2 μg/kg remifentanil (approval no. H20030200, Yichang Renfu Pharmaceutical Co., Ltd.), 1-2 mg/kg propofol (approval no. H20051843, Sichuan Guorui Pharmaceutical Co., Ltd.), and 0.05-0.10 mg/kg midazolam (approval no. H20113433, Jiangsu Enhua Pharmaceutical Co., Ltd.) were intravenously administered 30 min before operation. After the patient lost consciousness, the closed-loop muscle relaxant injection system was opened, and muscle relaxant drugs were given.

The patients in the experimental group A were anesthetized via cisatracurium besylate (approval no. H20060927, Dongying Pharmaceutical Co., Ltd.) with an induction dose of 0.15 mg/kg and a maintenance rate of 0.1 mg/(kg-h); patients in the experimental group B were given mivacurium chloride (approval no. H20100454, GlaxoSmithKline Manufacturing S.P.A) for anesthesia with an induction dose of 0.2 mg/kg and a maintenance rate of 0.15% mg/(kg h). Both groups were intubated through the orotracheal tube when the maximum inhibition was reached, and then, the anesthesia machine was connected and relevant parameters were adjusted. The respiratory rate was 12 times/min, the tidal volume was 8 ml/kg, and the inspiratory ratio was 1:2.

During the maintenance period, propofol + remifentanil + sevoflurane was given as follows: propofol 2 mg/kg was slowly pushed, and the bronchoscope was introduced when breathing and circulation were stable. During the operation, propofol was added intermittently depending on the patient’s response, and anesthesia was maintained by inhalation of sevoflurane; the dosage of remifentanil was adjusted according to the hemodynamics and respiratory rate, with an increase or decrease of 0.025 μg/(kg-min) each time. Inhalation was stopped 20 minutes before the end of the operation, and no muscle relaxant antagonist was used after the operation.

3.1. Observation Indicators. ① Monitoring devices are used to continuously monitor and record mean arterial pressure (MAP), heart rate (HR), and pulse oximetry (SpO2). The patients’ hemodynamic parameters are monitored at admission, during induction of anesthesia, during intubation, at the end of the procedure, at recovery of consciousness, and at extubation.

② Train of four (TOF) stimulations: the TOF values of the above six time points in the two groups of patients were compared.

③ Recovery situation: the recovery time of self-consciousness, extubation time, and eye-opening time and the occurrence of agitation in the two groups from the beginning of surgical anesthesia to 1 hour after extubation were compared between the two groups.

④ Adverse reactions: the occurrence of adverse reactions in the two groups after operation, including residual muscle relaxation, hypotension, bronchospasm, skin...
flushing, nausea, and vomiting, were observed and compared.

3.2. Statistical Analysis. The SPSS 22.0 software was used to process the data. The enumeration data (n (%)) and measurement data (x ± s) were examined via the chi-square and t tests, respectively. P < 0.05 was considered statistically significant.

4. Results

4.1. General Information. In the experimental group A, there were 28 males and 26 females, aged 25–61 years, with an average of 40.28 ± 4.87 years, and a BMI of 22–25 kg/m², with an average of 23.84 ± 1.21 kg/m². In the experimental group B, there were 27 females, aged 23–64 years, with an average age of 40.88 ± 3.97 years, and a BMI of 22–26 kg/m², with an average of 23.98 ± 1.08 kg/m². The baseline data were comparable between the two groups of patients (Table 1).

4.2. Hemodynamics. There was no significant difference in MAP, HR, and SpO₂ levels between the two groups at the six time points of admission, anesthesia induction, intubation, end of operation, recovery of consciousness, and extubation (all P < 0.05) (Tables 2–4).

4.3. TOF Value. The TOF values were similar at the three time points of admission, anesthesia induction, and intubation between the two groups of patients (all P > 0.05); whereas, TOF values (36.81 ± 8.23, 79.87 ± 2.56, and 90.62 ± 6.29) at end of operation, recovery of consciousness, and extubation were significantly higher than those of the experimental group A (25.18 ± 4.07, 59.89 ± 5.02, and 80.86 ± 3.68) (all P < 0.05) (Table 5).

4.4. Recovery. The recovery time of self-consciousness, extubation time, and eye-opening time (4.87 ± 1.02, 7.68 ± 1.41, and 9.82 ± 1.65) of the experimental group B were significantly shorter than those of the experimental group A (12.18 ± 1.34, 20.85 ± 6.32, and 25.94 ± 5.65), and the occurrence of agitation (3.70%) was significantly less than that of the experimental group A (20.37%) (all P < 0.05) (Table 6).

4.5. Adverse Reactions. In the experimental group A, there were 2 cases (3.70%) of residual muscle relaxation, 1 case of hypotension (1.85%), 2 cases of skin flushing (3.70%), 4 cases of nausea and vomiting (7.41%), and 0 case of residual muscle relaxation (0.00%); in the experimental group B, 0 case of hypotension (0.00%), 0 cases of skin flushing (0.00%), and 1 case of nausea and vomiting (1.85%), and the total incidence of adverse conditions in the experimental group B (1.85%) was significantly lower than that in the experimental group A (16.67%) (P < 0.05) (Table 7).

5. Discussion

Anesthesia for ENT surgery is one of the keys to ensure successful surgery. Surgical anesthesia requires the selection of appropriate anesthetic methods and drugs [18–20]. As tracheal intubation and surgery are accompanied by varying degrees of anesthesia and muscle relaxation, the inevitable residual neuromuscular blockade after surgery possesses a challenge to surgical anesthesia. The choice of drug or method should take into account the patient’s psychological and physiological status to ensure good anesthetic outcomes while controlling the magnitude of hemodynamic fluctuations [21].

Among the current clinical anesthetics, both cis-atracurium besylate and mivacurium chloride are good choices, and each has its own advantages. For example, the former has a remarkable muscle relaxation effect [22], while the latter is associated with fewer side reactions [23]. Currently, it remains controversial which is more effective. In line with our hypotheses, we found that there was no significant difference in MAP, HR, and SpO₂ levels between the two groups at the six time points of admission, anesthesia induction, intubation, end of operation, recovery of consciousness, and extubation; and TOF values were similar at the three time points of admission, anesthesia induction, and intubation between the two groups of patients; whereas, TOF values at end of operation, recovery of consciousness, and extubation were significantly higher than those of the experimental group A. However, this interpretation is supported by the fact that the rapid onset of action of mivacurium chloride and the absence of significant neuromuscular blockade accumulation as demonstrated by monitoring with a muscle relaxation monitor facilitated a reduction in depth of anesthesia towards the end of the procedure [23]. Possible explanations are that this study required a closed-loop myorelaxant injection, which allows for effective individualization of dosing and helps to avoid drug wastage due to long-term myorelaxant use; mivacurium chloride is a synthetic diquaternary compound with two ester bonds and therefore has a rapid onset of action and a short duration of action with an elimination half-life of 2–3 minutes, consistent with previous studies [24].

Also, in keeping with our hypotheses, we found that the recovery time of self-consciousness, extubation time, and eye-opening time of the experimental group B were significantly shorter than those of the experimental group A, and the occurrence of agitation was significantly less than that of the experimental group A. This would suggest that the recovery of muscle contraction function in patients receiving mivacurium chloride after otolaryngology surgery was better than using cisatracurium besylate. It is assumed that cisatracurium besylate is a nondepolarizing muscle relaxant due to its similar metabolism and myorelaxant effect to atracurium, although it has fewer side effects on the human cardiovascular system but a higher muscle relaxant effect [25, 26]; mivacurium chloride is a diquaternary ammonium compound that can be synthesized as a substitute for succinylcholine. It is a short-acting benzylisoquinoline nondepolarizing muscarinic agent with short duration of action,
Table 1: Baseline data (x ± s).

| Groups          | n   | Male | Female | Age (years) | Mean age (years) | BMI  | Mean BMI |
|-----------------|-----|------|--------|-------------|------------------|------|----------|
| Experimental A  | 54  | 28   | 26     | 25–61       | 40.28 ± 4.87     | 22–25| 23.84 ± 1.21 |
| Experimental B  | 54  | 27   | 27     | 23–64       | 40.88 ± 3.97     | 22–26| 23.98 ± 1.08 |
| T               | —   | —    | —      | —           | 0.341            | —    | 0.521     |
| P               | —   | —    | —      | —           | 0.798            | —    | 0.545     |

Table 2: Comparison of hemodynamics between the two groups of patients (x ± s).

| Groups          | n   | Upon admission | Anesthesia induction |
|-----------------|-----|----------------|----------------------|
|                 |     | MAP (mmHg)     | HR (times/min)       | SpO₂ (%)           | MAP (mmHg)     | HR (times/min) | SpO₂ (%) |
| Experimental A  | 54  | 103.12 ± 9.38  | 82.38 ± 7.21         | 97.73 ± 11.11      | 100.98 ± 7.21  | 79.82 ± 8.41  | 98.21 ± 10.29 |
| Experimental B  | 54  | 102.61 ± 10.33 | 83.54 ± 9.12         | 96.74 ± 11.98      | 101.01 ± 12.04 | 80.18 ± 10.63 | 98.11 ± 10.82 |
| t               | —   | 0.496          | 0.274                | 0.297              | 0.473          | 0.288         | 0.354     |
| P               | —   | 0.684          | 0.888                | 0.754              | 0.692          | 0.726         | 0.594     |

Table 3: Comparison of hemodynamics between the two groups of patients (x ± s).

| Groups          | n   | Intubation | End of operation |
|-----------------|-----|------------|------------------|
|                 |     | MAP (mmHg) | HR (times/min)   | SpO₂ (%)          | MAP (mmHg)     | HR (times/min) | SpO₂ (%) |
| Experimental A  | 54  | 115.41 ± 6.02 | 74.53 ± 6.21       | 99.65 ± 14.52     | 109.65 ± 9.11  | 70.41 ± 8.01  | 99.51 ± 10.02 |
| Experimental B  | 54  | 112.88 ± 9.63 | 75.42 ± 11.02      | 99.81 ± 10.32     | 105.12 ± 7.63  | 70.52 ± 9.45  | 99.98 ± 11.41 |
| t               | —   | 0.357       | 0.294              | 0.456             | 0.461          | 0.213         | 0.323     |
| P               | —   | 0.702       | 0.813              | 0.582             | 0.598          | 0.814         | 0.757     |

Table 4: Comparison of TOF values between the two groups of patients (x ± s).

| Groups          | n   | Upon admission | Anesthesia induction | Intubation | End of operation |
|-----------------|-----|----------------|----------------------|------------|------------------|
|                 |     | MAP (mmHg)     | HR (times/min)       | SpO₂ (%)  | MAP (mmHg)     | HR (times/min) | SpO₂ (%) |
| Experimental A  | 54  | 99.36 ± 12.68  | 99.15 ± 10.68        | 0.00 ± 0.00 | 25.18 ± 4.07  | 59.89 ± 5.02  | 80.86 ± 3.68 |
| Experimental B  | 54  | 99.54 ± 12.05  | 99.24 ± 6.88         | 0.00 ± 0.00 | 36.81 ± 8.23  | 79.87 ± 2.56  | 90.62 ± 6.29 |
| t               | —   | 0.024          | 0.276                | 0.268      | 0.703          | 0.058         | 0.123     |
| P               | —   | 0.997          | 0.683                | 0.759      | 0.484          | 0.996         | 0.624     |

Table 5: Comparison of recovery of the two groups of patients (x ± s, %).

| Groups          | n   | Self-consciousness recovery time (min) | Extubation time (min) | Eye-opening time (min) | Cases of agitation occurs (n) |
|-----------------|-----|--------------------------------------|-----------------------|-----------------------|-------------------------------|
| Experimental A  | 54  | 12.18 ± 1.34                         | 20.85 ± 6.32          | 25.94 ± 5.65          | 11 (20.37)                    |
| Experimental B  | 54  | 4.87 ± 1.02                          | 7.68 ± 1.41           | 9.82 ± 1.65           | 2 (3.70)                      |
| t               | —   | 13.254                               | 15.667                | 19.024                | 8.945                         |
| P               | —   | < 0.001                              | < 0.001               | < 0.001               | 0.002                         |
studies. Analysis after follow-up investigations in follow-up time, and we need to conduct more in-depth way ANOVA. Second, many indicators are related to the multiple time points in our experiments required a one-factors in the experiment. First, comparisons between clinical application. However, there are many limiting reactions, and higher safety. Overall, it merits widespread accumulation of neuromuscular blockade, less adverse reactions, and rapid recovery [27, 28]. It has relatively few autonomic and cardiovascular side effects. After discontinuation of the drug, the patient can regain muscle tone naturally within a short period of time [29].

As previously noted, both cisatracurium besylate and mivacurium chloride anesthesia will cause different degrees of damage to patients and lead to adverse reactions. The adverse effect profile of mivacurium anesthesia is related to histamine release and dose, but can be reduced by splitting or adjusting the time of administration. It is also of interest that the treatment in the experimental group B was associated with lower incidence of adverse reactions. We suggest this is perhaps because the application of mivacurium chloride anesthesia can reduce the occurrence of residual muscle relaxation during the recovery period and after recovery, playing a positive role on both mental and physical recovery of patients after surgery, and the data support findings of the trial of Farhan et al. [30].

Adverse reactions that have been recorded with atracurium cisbenzoate include skin flushing or rash, bradycardia, hypotension, and bronchospasm. Allergic reactions of varying degrees of severity can be observed following the use of neuromuscular blocking agents [31]. In rare cases, severe allergic reactions have been reported when this product is combined with one or more anesthetic agents [32]. Myasthenia and/or myopathy have been reported in severely ill patients in intensive care units after prolonged use of muscle relaxants [33]. Most patients received concomitant steroid preparations, and these have occasionally been reported following the use of this product, but the causal relationship has not been established [34].

6. Conclusion

To sum up, compared with cisatracurium besylate in otolaryngology surgery, mivacurium chloride anesthesia offers a promising route with respect to less impact on hemodynamics, faster postoperative recovery, absence of the accumulation of neuromuscular blockade, less adverse reactions, and higher safety. Overall, it merits widespread clinical application. However, there are many limiting factors in the experiment. First, comparisons between multiple time points in our experiments required a one-way ANOVA. Second, many indicators are related to the follow-up time, and we need to conduct more in-depth analysis after follow-up investigations in follow-up studies.

| Groups               | n   | Muscle relaxation remnants | Low blood pressure | Flushing of the skin | Nausea and vomiting | Total incidence |
|----------------------|-----|----------------------------|--------------------|----------------------|---------------------|-----------------|
| Experimental group A | 54  | 2 (3.70)                   | 1 (1.85)           | 2 (3.70)             | 4 (7.41)            | 9 (16.67)       |
| Experimental group B | 54  | 0 (0.00)                   | 0 (0.00)           | 0 (0.00)             | 1 (1.85)            | 1 (1.85)        |
| t                    | —   | 8.804                      |                    |                      |                     |                 |
| P                    | —   | 0.003                      |                    |                      |                     |                 |

Data Availability

The data generated or analyzed during this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] A. T. Waberski, A. G. Espinel, and S. K. Reddy, "Anesthesia safety in otolaryngology," Otological Clinic of North America, vol. 52, no. 1, pp. 63–73, 2019.
[2] N. R. Kolia and L. X. Man, "Total intravenous anaesthesia versus inhaled anaesthesia for endoscopic sinus surgery: a meta-analysis of randomized controlled trials," Rhinology, vol. 57, no. 6, pp. 402–410, 2019.
[3] W. A. Wetsch, D. Beutner, K. J. Stuermer, and S. A. Padosch, "Specific aspects of anaesthesiological management of laser surgery in otorhinolaryngology," Anaesthesist, vol. 63, no. 6, pp. 519–530, 2014.
[4] P. Pelosi, M. Croci, I. Ravagnan et al., "The effects of body mass on lung volumes, respiratory mechanics, and gas exchange during general anesthesia," Anesthesia & Analgesia, vol. 87, no. 3, pp. 654–660, 1998.
[5] H. M. Sohn and J. H. Ryu, "Monitored anesthesia care in and outside the operating room," Korean J Anesthesiol, vol. 69, no. 4, pp. 319–326, 2016.
[6] J. J. Savarese, C. A. Lien, M. R. Belmont, and W. B. Wasitla, "[The clinical pharmacology of new benzylisoquinoline-diest er compounds, with special consideration of cisatracurium and mivacurium]." Anaesthesist, Der, vol. 46, no. 10, pp. 840–849, 1997.
[7] X. Huang, L. Chen, Y. Cai et al., "Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction," BMC Anesthesiology, vol. 20, no. 1, p. 21, 2020.
[8] H. Mellinghoff, L. Radbruch, C. Diefenbach, and W. Buzello, "A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion," Anesthesia & Analgesia, vol. 83, no. 5, pp. 1072–1075, 1996.
[9] Y. J. Dong and X. Li, "Comparative study on the pharmacodynamics of cisatracurium: continuous infusion or intermittent bolus injection," Contemporary Clinical Trials, vol. 33, no. 3, pp. 482–485, 2012.
[10] C. Diefenbach and W. Buzello, "[New muscle relaxants]," Anesthesiol Intensivmed Notfallmed Schmerzther, vol. 31, no. 1, pp. 2–8, 1996.
[11] C. Xuan, N. Wu, Y. Li, X. Sun, Q. Zhang, and H. Ma, "Corrected QT interval prolongation during anesthetic induction for laryngeal mask airway insertion with or without
cisatracurium,” *Journal of International Medical Research*, vol. 46, no. 5, pp. 1990–2000, 2018.

[12] S. Feldman, “Mivacurium,” *British Journal of Hospital Medicine*, vol. 57, no. 5, pp. 199–201, 1997.

[13] L. E. Vanlinthout, S. H. Mesfin, N. Hens, B. F. Vanacker, E. N. Robertson, and L. H. Boori, “A systematic review and meta-regression analysis of mivacurium for tracheal intubation,” *Anaesthesia*, vol. 69, no. 12, pp. 1377–1387, 2014.

[14] J. R. Ortiz and F. Carrascosa, “Mivacurium,” *Revista Espanola de Anestesiologia y Reanimacion*, vol. 44, no. 8, pp. 315–320, 1997.

[15] C. H. Koo, S. H. Chung, B. G. Kim et al., “Comparison between the effects of deep and moderate neuromuscular blockade during transurethral resection of bladder tumor on endoscopic surgical condition and recovery profile: a prospective, randomized, and controlled trial,” *World Journal of Urology*, vol. 37, no. 2, pp. 359–365, 2019.

[16] T. C. Wicks, “Mivacurium chloride,” *Nurse Anesthesia*, vol. 3, no. 4, pp. 173–182, 1992.

[17] C. Diffenbach, W. Buzello, and H. Mellinghoff, “Mivacurium chloride—a comparative profile,” *Acta Anaesthesiologica Scandinavica - Supplementum*, vol. 106, pp. 23–25, 1995.

[18] A. Henn-Beilharz, W. Ullrich, R. Georgi, and F. Kienzle, “[Anesthesia for maxillofacial, ear, nose and throat surgery, otorhinolaryngology in ophthalmic procedures. 2. Specific aspects of otorhinolaryngology in ophthalmic procedures],” *Anesthesiol Intensivmed Notfallmed Schmerzther*, vol. 34, no. 3, pp. 147–170, 1999.

[19] R. K. Meacham and J. Schindler, “Anesthesia care for the professional singer,” *Anesthesiol Clin*, vol. 33, no. 2, pp. 347–356, 2015.

[20] G. Burnett, S. DeMaria, and A. I. Levine, “Regional anesthesia and acute pain management,” *Otolaryngologic Clinics of North America*, vol. 52, no. 6, pp. 1065–1081, 2019.

[21] B. J. King and A. Levine, “Controversies in anesthesia for oral and maxillofacial surgery,” *Oral and Maxillofacial Surgery Clinics of North America*, vol. 29, no. 4, pp. 515–523, 2017.

[22] J. Pignard, D. Bourdeaux, S. Kauffmann, J. M. Constantin, and V. Sautou, “[Physicochemical stability study of injectable solutions of cisatracurium besilate in clinical conditions],” *Annales Francaises d’Anesthesie et de Reanimation*, vol. 33, no. 5, pp. 304–309, 2014.

[23] S. J. Basta, “Clinical pharmacology of mivacurium chloride: a review,” *Journal of Clinical Anesthesia*, vol. 4, no. 2, pp. 153–163, 1992.

[24] T. Raghavendra, “Neuromuscular blocking drugs: discovery and development,” *Journal of the Royal Society of Medicine*, vol. 95, no. 7, pp. 363–367, 2002.

[25] C. Lee, “Conformation, action, and mechanism of action of neuromuscular blocking muscle relaxants,” *Pharmacology & Therapeutics*, vol. 98, no. 2, pp. 143–169, 2003.

[26] R. G. Craig and J. M. Hunter, “Neuromuscular blocking drugs and their antagonists in patients with organ disease,” *Anaesthesia*, vol. 64, pp. 55–65, 2009.

[27] D. R. Bevan, “Newer neuromuscular blocking agents,” *Pharmacology & Toxicology*, vol. 74, no. 1, pp. 3–9, 1994.

[28] I. R. Morris, “Pharmacologic aids to intubation and the rapid sequence induction,” *Emergency Medicine Clinics of North America*, vol. 6, no. 4, pp. 753–768, 1981.

[29] J. I. Savarese and W. B. Wastila, “The future of the benzylisoquinolinium relaxants,” *Acta Anaesthesiologica Scandinavica*, vol. 39, pp. 91–93, 1995.

[30] H. Farhan, I. Moreno-Duarte, D. McLean, and M. Eikermann, “Residual paralysis: does it influence outcome after ambulatory surgery?” *Current Anesthesiology Reports*, vol. 4, no. 4, pp. 290–302, 2014.

[31] N. Wang, Y. Zhang, Y. Hu, Q. Yang, and Z. Su, “Serious bronchospasm induced by cisatracurium besylate: a case report,” *Medicine (Baltimore)*, vol. 100, no. 15, Article ID e25516, 2021.

[32] N. A. Fernandopulle, S. S. Zhang, P. F. Soeding, and G. A. Mackay, “MRGPRX2 activation in mast cells by neuromuscular blocking agents and other agonists: modulation by sugammadex,” *Clinical and Experimental Allergy*, vol. 51, no. 5, pp. 685–695, 2021.

[33] R. E. Barnette, I. R. Kamel, L. Fermin, and G. J. Criner, “Use of neuromuscular blocking agents in the intensive care unit,” *InCritical Care Study Guide*, Springer, Berlin, Germany, 2010.

[34] K. L. Cosford and S. T. Koo, “In-hospital medical management of feline urethral obstruction: a review of recent clinical research,” *Canadian Veterinary Journal*, vol. 61, no. 6, p. 595, 2020.